Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Gilbert

Showing results (341-350 of 453) with videos related to

Pageof 46
Sort By:
JCI Insight|September 20, 2019
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNKAmber J Giles, Shuyu Hao, Michelle Padget, et al.
Oncotarget|June 18, 2020
Efficacy of osimertinib against EGFRvIII+ glioblastomaGustavo Chagoya, Shawn G Kwatra, Cory W Nanni, et al.
International Journal of Radiation Oncology, Biology, Physics|May 7, 2023
Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001Vinai Gondi, Snehal Deshmukh, Paul D Brown, et al.
Neuro-Oncology|February 21, 2018
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group databaseDeborah T Blumenthal, Minhee Won, Minesh P Mehta, et al.
Cell|April 15, 2021
Synthetic lethality-mediated precision oncology via the tumor transcriptomeJoo Sang Lee, Nishanth Ulhas Nair, Gal Dinstag, et al.
Cancer|October 26, 2018
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastomaStefania Maraka, Morris D Groves, Aaron G Mammoser, et al.
Neuro-Oncology|August 5, 2011
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Jennifer L Clarke, Michele M Ennis, W K Alfred Yung, et al.
Journal of Neuro-Oncology|June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomaAndrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.
Acta Neuropathologica|February 1, 2022
High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13Drew Pratt, Zied Abdullaev, Antonios Papanicolau-Sengos, et al.
Brain Pathology (Zurich, Switzerland)|May 27, 2025
cIMPACT-NOW update 10: Recommendations for defining new types for central nervous system tumor classificationCynthia Hawkins, Kenneth Aldape, David Capper, et al.
Pageof 46

Showing results (341-350 of 453) with videos related to

Sort By:
Pageof 46
JCI Insight|September 20, 2019
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNKAmber J Giles, Shuyu Hao, Michelle Padget, et al.
Oncotarget|June 18, 2020
Efficacy of osimertinib against EGFRvIII+ glioblastomaGustavo Chagoya, Shawn G Kwatra, Cory W Nanni, et al.
International Journal of Radiation Oncology, Biology, Physics|May 7, 2023
Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001Vinai Gondi, Snehal Deshmukh, Paul D Brown, et al.
Neuro-Oncology|February 21, 2018
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group databaseDeborah T Blumenthal, Minhee Won, Minesh P Mehta, et al.
Cell|April 15, 2021
Synthetic lethality-mediated precision oncology via the tumor transcriptomeJoo Sang Lee, Nishanth Ulhas Nair, Gal Dinstag, et al.
Cancer|October 26, 2018
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastomaStefania Maraka, Morris D Groves, Aaron G Mammoser, et al.
Neuro-Oncology|August 5, 2011
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Jennifer L Clarke, Michele M Ennis, W K Alfred Yung, et al.
Journal of Neuro-Oncology|June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomaAndrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.
Acta Neuropathologica|February 1, 2022
High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13Drew Pratt, Zied Abdullaev, Antonios Papanicolau-Sengos, et al.
Brain Pathology (Zurich, Switzerland)|May 27, 2025
cIMPACT-NOW update 10: Recommendations for defining new types for central nervous system tumor classificationCynthia Hawkins, Kenneth Aldape, David Capper, et al.
Pageof 46